NuCana (NCNA) Liabilities and Shareholders Equity (2016 - 2025)

NuCana (NCNA) reported Liabilities and Shareholders Equity of $39.7 million for Q4 2025, up 109.28% on a YoY basis from $19.0 million in Q4 2024, and down 8.99% sequentially from $43.6 million in Q3 2025.

NuCana (NCNA) Liabilities and Shareholders Equity (2016 - 2025) Analysis & Trends

NuCana (NCNA) has 10 years of Liabilities and Shareholders Equity data on file, last reported at $39.7 million in Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 109.28% year-over-year to $39.7 million; the trailing twelve-month figure through Dec 2025 stood at $119.5 million (up 18.19% YoY), and the FY2025 full-year result was $39.3 million, up 108.29% from the prior year.
  • Liabilities and Shareholders Equity slipped to $39.7 million in Q4 2025, from $43.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $139.1 million in Q1 2021 to a low of $14.6 million in Q1 2025.
  • A 5-year average of $61.7 million and a median of $47.6 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
  • Peak annual rise in Liabilities and Shareholders Equity reached 109.28% in 2025, while the deepest fall reached 53.56% in 2025.
  • Tracing NCNA's Liabilities and Shareholders Equity over 5 years: stood at $104.4 million in 2021, then slumped by 34.57% to $68.3 million in 2022, then plunged by 49.48% to $34.5 million in 2023, then sank by 45.06% to $19.0 million in 2024, then surged by 109.28% to $39.7 million in 2025.
  • Business Quant data shows NCNA's Liabilities and Shareholders Equity at $39.7 million in Q4 2025, $43.6 million in Q3 2025, and $21.6 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 311.58 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 78.88 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 8.55 Bn
4 NuCana 279.75 Bn 279.75 Bn - 39.68 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 26.48 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 40.87 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - 811.27 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 10.03 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 2.25 Bn
10 Alnylam Pharmaceuticals 35.71 Bn 32.70 Bn 959.66 Mn 5.13 Bn

Historic Data

Download Data
DateValue
Dec 31, 2025 39.68 Mn
Sep 30, 2025 43.60 Mn
Jun 30, 2025 21.64 Mn
Mar 31, 2025 14.61 Mn
Dec 31, 2024 18.96 Mn
Sep 30, 2024 25.38 Mn
Jun 30, 2024 25.33 Mn
Mar 31, 2024 31.46 Mn
Dec 31, 2023 34.52 Mn
Sep 30, 2023 43.03 Mn
Jun 30, 2023 51.63 Mn
Mar 31, 2023 59.26 Mn
Dec 31, 2022 68.33 Mn
Sep 30, 2022 80.92 Mn
Jun 30, 2022 83.91 Mn
Mar 31, 2022 95.84 Mn
Dec 31, 2021 104.44 Mn
Sep 30, 2021 123.78 Mn
Jun 30, 2021 129.04 Mn
Mar 31, 2021 139.09 Mn